Advanced Cancer Pain Management Market

Market Insights on Advanced Cancer Pain Management covering sales outlook, demand forecast & up-to-date key trends

Advanced Cancer Pain Management Market by Drug Class, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033

Request Sample Talk to Analyst

Advanced Cancer Pain Management Market Outlook

The global advanced cancer pain management market is anticipated to attain a valuation of US$ 7,265.44 million in 2023 and is estimated to reach US$ 11,540 million by 2033, trailing a CAGR of 4.74% during the forecast period.

With the rising prevalence of cancer, the awareness for the disease as well as the cancer induced pain is also increasing. This is leading to the increasing healthcare expenditure for diagnosis and therapeutics of the cancer related pain.

According to the Organization for economic cooperation and development, the preliminary estimates of healthcare spending for a group of 16 OECD countries jumped to about 10% of GDP in 2020. Thus, the surging healthcare expenditure and government support across the globe is expected to fuel growth of advance cancer pain management market.

Report Attribute	Details
Expected Market Value (2023)	US$ 7265.44 million
Anticipated Forecast Value (2033)	US$ 11540 million
Projected Growth Rate (2023 to 2033)	CAGR 4.74%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Advanced cancer pain treatment Demand Analysis vs. Forecast 2023 to 2033

The industry for advanced cancer pain management recorded a valuation of US$ 6,150 million in 2018, while growing at a CAGR of 3.39 % during the historical period. There are various marketed drugs in the market by several companies. For example, ULTRAM (tramadol hydrochloride) by Janssen Ortho, LLC; Hydromorphone Hydrochrloride by Janssen Korea, Limited, Oxycodone by Taiwan Mundipharma Pharmaceuticals Ltd, and Lazanda (Fentanyl) by Insys Therapeutics, Inc., among others. These drugs are expected to present growth opportunities for the market of advanced cancer pain treatment in the upcoming years.

Various market players are also investing in research and development activities for development of more effective drugs for the treatment of advanced cancer pain. Some of these emerging drugs include Morphine sulfate by Tetra Biopharma/Cognitive Research Corporation, Resiniferatoxin by Sorrento Therapeutics, Inc., and Pregabalin by Institut Cancerologie de l'Ouest/Grunenthal GmbH. Likewise, Sorrento's resiniferatoxin received Food and drug administration’s clearance for proceeding with its Phase two clinical study for using epidural resiniferatoxin as a therapeutic medicine for intractable pain related with advanced cancer.

On the other hand, Patients suffering from advanced or metastatic cancer cannot be treated for cancer pain only with analgesics. They require invasive techniques like peripheral nerve blockers and neuraxial analgesia for vertebral pain, among others. Surging advancements in nerve blockers to improve pain control and offer long-term relief to advanced cancer patients are also anticipated to drive market revenue growth during the forecast period. Considering the above-mentioned factors and new developments, the revenue growth of Advanced cancer pain treatment market is projected to be worth US$ 11,540 million by end of the forecast period, while exhibiting a CAGR of 4.74%.

Which are Some Prominent Drivers spearheading the Advanced Cancer Pain Management Market?

Availability of effective therapies and increasing healthcare expenditure driving market growth

The growth of the global advanced cancer pain treatment market is primarily driven by rising prevalence of cancer; growth in geriatric population, increasing healthcare expenditure and mounting investments in research and development activities by various healthcare companies. For example, according to American Cancer Society, nearly 1.80 million new cancer cases were diagnosed and about 606,525 cancer deaths were observed in the United States, in 2020. Also, according to the International Agency for Research on Cancer, approximately 1,065,960 new cases were reported for colorectal cancer worldwide in 2020. This rising trend in cancer cases will create market space for the expansion of cancer pain management market during the forecast period.

The geriatric population is more susceptible to various types of cancers, such as lung cancer, renal cancer, bladder cancer, melanoma, and others, owing to aging effect and mutation in the gene. According to the National Cancer Institute, the average age for diagnosis is 60 years for breast cancer, 67 years for colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer. Moreover, according to the Medicare and Medicaid Services, the National Health Expenditure reached $3.80 trillion in 2019. The National health expenditure increased by 4.6% in 2019, and accounted for approximately 17.7% of the United States GDP. Increase in demand for monoclonal antibodies for the treatment of cancer induced pain is also expected to boost growth of the advanced cancer pain market.

Also, availability of effective therapies and growing focus on relieving advanced cancer pain are leading to advancements in understanding the etiology and pathophysiology of cancer pain that is benefiting the market. Furthermore, surging investments and efforts to develop comprehensive approach to classify cancer pain due to growing emphasis on proper management and treatment of advanced cancer pain are also anticipated to drive market growth during the forecast period.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the challenges expected to be Faced by the Market?

Adverse effects to restrain market growth

Side-effects associated with the use of drugs employed in cancer pain treatment such as drug tolerance, dependence on drugs, urinary retention, sleep disorders, cognitive impairment, and others are anticipated to hamper the cancer pain market growth over the forecast period.

Also, dearth of awareness among clinicians in effective management of cancer pain, absence of opioids in developing countries, and dearth of established healthcare infrastructure in low- and middle-income countries are some key factors anticipated to restrain market growth during the forecast period.

Region-Wise Insights

What are the growth prospects in North America?

North America dominates the market with maximum share

North America is expected to dominate the market of Advanced cancer pain treatment by accounting for 42.9% market share by end of the forecast period. This region is anticipated to retain its dominance during the forecast period, due to growing prevalence of cancer, technological advancements in healthcare, easy access and availability of pain therapeutics, and availability of better-quality chemotherapy treatment options.

The growth in this region is also attributed to favorable healthcare infrastructure, which encourages easy access to advanced pain management devices. Furthermore, rising government initiatives, like Precision Medicine and Affordable Care Act, along with a well-planned reimbursement policy in this region is supporting market growth. The regional market is also propelled by the presence of robust healthcare facilities, surging aging population, and rising incidences of hypertension and stroke. With the increase in elderly population, the market is anticipated to show a higher growth rate, as the elder population is at greater risk of severe illness. Thus, leading to market growth in the region.

What is the growth outlook in Asia Pacific?

Asia Pacific driving growth with fastest CAGR

The market in Asia Pacific is projected to exhibit fastest CAGR of 5.5% during the forecast period. The growth is attributable to increasing incidence of cancer, rapid advancements in cancer research, development of strong therapeutic pipeline, easy availability of advanced cancer drugs, and growing focus on palliative and end-of-life care.

This growth can also be attributed to research and developments investments in producing technologically advanced healthcare therapeutic options. Furthermore, the presence of numerous trade agreements is also leading to market growth in the region. For example, the Asia Pacific Trade Agreement between China, India, Bangladesh, Lao PDR, Republic of Korea, Mongolia, and Sri Lanka has encouraged trade liberalization and increased import and export opportunities amongst participating nations. This will lead to market growth in this region.

In addition, strengthening of healthcare infrastructure, growing per capita income, increasing geriatric population, and increasing prevalence of advance chronic pain in the region is leading to market growth. According to the United Nations Department of Economic and Social Affairs report on world population aging, the number of elderly people in Asia is anticipated to increase by two-fold, from 394 million in 2019 to 588 million by 2030. Elderly people are at a greater risk of chronic pain conditions, like arthritis, neuropathic disorders, and back pain, which, in turn, drives the demand for drugs and devices for the treatment of chronic pain including cancer pain.

Category wise Insights

By Drug Class, Which Segment will possess Market Hegemony?

Cannabinoids driving growth with significant market share

The cannabinoids segment dominated the market in 2021, and is anticipated to continue the trend during the forecast period by reaching market share of 35% by end of the forecast period. The growth is attributed to rising prevalence of severe cancer pain, surge in adoption of cannabinoids in the treatment of cancer pain, and robust presence of pipeline drugs.

A significant number of patients are turning to cannabis and cannabinoids for management of their palliative and nonpalliative cancer pain and other cancer-associated symptoms which is expected to drive growth of this segment.

A cohort study using ‘nabiximols’ on advanced cancer pain in patients already using opioids, over 3 weeks, showed improved average pain score. A large observational study of cancer patients using cannabis over 6 months showed a reduced number of patients with acute pain and reduced opioid use, whereas the number of patients reporting good quality of life were increased. Good preclinical animal data and a vast body of observational evidence point to the potential effectiveness of cannabinoids for cancer pain treatment.

Which segment will dominate the market by route of administration?

Intravenous segment driving industry growth with dominating share

This segment is anticipated to dominate the market of advance cancer pain management market by accumulating a market share of 78% by end of the forecast period. This segment is also expected to grow with fastest CAGR of 8.9% during the forecast period. Intravenous administration offers various advantages like high bioavailability of pain medications, better dose control and administration rate, and generation of stable pharmacodynamics and pharmacokinetics profiles. This is anticipated to boost adoption of intravenous route of administration during cancer pain management therapies. Also, intravenous administration of morphine allows better management of pain in patients suffering from severe cancer pain, for breakthrough pain, and in patients with weak pain control under high opioid dosages, which is anticipated to further boost revenue growth of the segment during the forecast period.

By Distribution Channel, which segment is expected to dominate the market?

Hospital Pharmacies to drive growth with maximum market share

Hospital pharmacies are expected to dominate the market of advance cancer pain management by reaching 67.2% market share by end of the forecast period. This segment is also anticipated to grow with fastest CAGR of 7.6% during the projected period. Factors such as growing preference and trust of suffered patients towards hospital environments, government focus on strengthening healthcare infrastructure, easy access to treatment facilities are some factors leading to the growth of this segment. Furthermore, the drugs developed by various industry companies after intense research and development activities directly benefits the hospital pharmacies. This will also contribute to expansion of this segment in the forecast period.

Start-ups in Advanced cancer pain management market

Start-ups help in determining the future growth opportunities in any market. These new entrants have the potential to generate high returns which directly benefits the expansion of any industry. These start-ups are typically more efficient at transforming inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to sensitive market conditions. Some of the start-ups that will bolster the expansion of Advanced cancer pain management market are:

‘Grow Group’ is a London, United Kingdom-based developer of cannabis-based medicines for multiple indications. It was founded in 2017. This start-up discovers and develops cannabis-based medicine for treating chronic pain like neuropathic pain, cancer induced pain, epileptic seizures, spasticity, and drug addictions. It also provides Calyx app to track health, medicine, and activities. It was granted funding of USD 13 million.
‘ZYUS life sciences’ is a Saskatoon, Canada-based start-up that develops cannabis-derived therapeutics for multiple indications. It was founded in 2018. This company is focusing on developing cannabinoid-based therapeutics and protein-based formulations to provide targeted relief for patients. The lead drug candidate of the company is Trichomylin which alleviates chronic pain. This start-up gathered a funding of USD 20 million from ‘Keyhorse Capital’
Founded in 2012, ‘Junshi Biopharma’ is a Shanghai based start-up that offers antibody-based therapeutics for multiple diseases. The drug candidates of this company include anti-PD-1 monoclonal antibodies, PCSK9 monoclonal antibodies, anti-BLyS monoclonal antibodies, and few others for treatment of cancer, metabolic, neurology, immunology, and infectious diseases. It received funding of USD 31.5 million in 2018.

Market Competition

The advanced cancer pain management market is extremely competitive and consists of several industry players. These players are developing novel delivery systems for treating Advanced cancer pain management. This is estimated to propel advanced cancer pain management market. The key players in this industry are: WEX Pharmaceuticals Inc, Jazz Pharmaceuticals, Nobelpharma Co., Ltd, Tetra Bio-Pharma Inc., Pfizer, Recipharm, eurofins, Sigma-Aldrich, AstraZeneca, GlaxoSmithKline plc. Key market players are tending towards adoption of inorganic growth strategies like acquisition, mergers, partnerships, and collaboration in order to strengthen their product portfolio. This is anticipated to fuel the global Advanced cancer pain management market.

In October 2022, Parker Laboratories Inc., which develops, manufactures, and sells pain relief creams, ultrasound and electromedical contact media, and institutional cleaners and disinfectants, is increasing its analgesics line. The company has added Helix CBD Therapy Cream, CBD Clinical Cream, and Tri-Active Therapy Cream to its HelixTM line.
In September 2022, Compass Group Equity Partners which is a St. Louis-based private equity firm, declared a strategic partnership with Mays & Schnapp Neurospine and Pain ("Mays & Schnapp"), based in Memphis, interventional pain management practice serving patients in Tennessee and Mississippi.
In July 2021, Venus Remedies Limited announced launch of a consumer healthcare division that will provide various products for pain management.
In January 2021, Boston Scientific Corporation announced the launch of Wave Writer Alpha, a portfolio of spinal cord stimulator systems that combine therapy options for personalized pain relief.

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 7,265.44 million
Market Value in 2033	US$ 11,540 million
Growth Rate	CAGR of 4.74% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Drug Class Route of Administration Distribution Channel Region
Regions Covered	North America Latin America Europe Asia Pacific Middle East and Africa
Key Countries Profiled	USA Canada Brazil Mexico Germany United Kingdom France Spain Italy India China Japan Indonesia Singapore Thailand South Korea Australia New Zealand GCC Countries South Africa Israel
Key Companies Profiled	WEX Pharmaceuticals Inc. Jazz Pharmaceuticals Nobelpharma Co., Ltd Tetra Bio-Pharma Inc. Pfizer Recipharm eurofins Sigma-Aldrich AstraZeneca GlaxoSmithKline plc
Customization	Available Upon Request

Key Segments Profiled in the Advanced Cancer Pain Management Industry Survey

By Drug Class:

• Monoclonal Antibody
• Cannabinoid
• Aminoindane

By Route of Administration:

Intravenous
Oral
Inhalational

By Distribution Channel:

Hospital pharmacies
Retail pharmacies
Online pharmacies

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa

Frequently Asked Questions

What is the anticipated growth of the Advanced cancer pain management market until 2033?

FMI projects the global Advanced cancer pain management market to expand at 4.74% value CAGR by 2033.

What is the estimated market value of the Advanced cancer pain management market expected in 2033?

The global Advanced cancer pain management market is expected to garner a market value of US$ 11540 million by 2033.

Which region is forecast to be the most lucrative for Advanced cancer pain management market growth?

FMI has projected North America to be one of the most profitable regions for Advanced cancer pain management market.

Which region is expected to grow fastest during the forecast period?

Asia Pacific is anticipated to grow fastest during the forecast period.

By drug class, which segment is expected to dominate the market by 2033?

Cannabinoids segment is expected to dominate the market by drug class during the forecast period.

By distribution channel, which segment is most likely to lead Advanced cancer pain treatment industry?

Hospital pharmacies are projected to lead the market with maximum share by end of the forecast period.

What was the market value of Advanced cancer pain management in 2018?

The market value of Advanced cancer pain management market was worth USD 6150 million in 2018.

What is the expected market share of Advanced cancer pain management in North America?

The market in North America is projected to account for 42.9% market share by end of the forecast period.

Table of Content

1. Executive Summary | Advanced Cancer Pain Management Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

5.3.1. Monoclonal Antibody

5.3.2. Cannabinoid

5.3.3. Aminoindane

5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

6.3.1. Intravenous

6.3.2. Oral

6.3.3. Inhalational

6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

7.1. Introduction / Key Findings

7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

7.3.1. Hospital Pharmacies

7.3.2. Retail Pharmacies

7.3.3. Online Pharmacies

7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

8.1. Introduction

8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

8.3.1. North America

8.3.2. Latin America

8.3.3. Europe

8.3.4. Asia Pacific

8.3.5. MIDDLE EAST AND AFRICA

8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

9.2.1. By Country

9.2.1.1. USA

9.2.1.2. Canada

9.2.2. By Drug Class

9.2.3. By Route of Administration

9.2.4. By Distribution Channel

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Drug Class

9.3.3. By Route of Administration

9.3.4. By Distribution Channel

9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. Brazil

10.2.1.2. Mexico

10.2.1.3. Rest of Latin America

10.2.2. By Drug Class

10.2.3. By Route of Administration

10.2.4. By Distribution Channel

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Drug Class

10.3.3. By Route of Administration

10.3.4. By Distribution Channel

10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. Germany

11.2.1.2. United Kingdom

11.2.1.3. France

11.2.1.4. Spain

11.2.1.5. Italy

11.2.1.6. Rest of Europe

11.2.2. By Drug Class

11.2.3. By Route of Administration

11.2.4. By Distribution Channel

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Drug Class

11.3.3. By Route of Administration

11.3.4. By Distribution Channel

11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.2.1. By Country

12.2.1.1. China

12.2.1.2. Japan

12.2.1.3. South Korea

12.2.1.4. Singapore

12.2.1.5. Thailand

12.2.1.6. Indonesia

12.2.1.7. Australia

12.2.1.8. New Zealand

12.2.1.9. Rest of Asia Pacific

12.2.2. By Drug Class

12.2.3. By Route of Administration

12.2.4. By Distribution Channel

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Drug Class

12.3.3. By Route of Administration

12.3.4. By Distribution Channel

12.4. Key Takeaways

13. MIDDLE EAST AND AFRICA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

13.2.1. By Country

13.2.1.1. GCC Countries

13.2.1.2. South Africa

13.2.1.3. Israel

13.2.1.4. Rest of MIDDLE EAST AND AFRICA

13.2.2. By Drug Class

13.2.3. By Route of Administration

13.2.4. By Distribution Channel

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Drug Class

13.3.3. By Route of Administration

13.3.4. By Distribution Channel

13.4. Key Takeaways

14. Key Countries Market Analysis

14.1. USA

14.1.1. Pricing Analysis

14.1.2. Market Share Analysis, 2022

14.1.2.1. By Drug Class

14.1.2.2. By Route of Administration

14.1.2.3. By Distribution Channel

14.2. Canada

14.2.1. Pricing Analysis

14.2.2. Market Share Analysis, 2022

14.2.2.1. By Drug Class

14.2.2.2. By Route of Administration

14.2.2.3. By Distribution Channel

14.3. Brazil

14.3.1. Pricing Analysis

14.3.2. Market Share Analysis, 2022

14.3.2.1. By Drug Class

14.3.2.2. By Route of Administration

14.3.2.3. By Distribution Channel

14.4. Mexico

14.4.1. Pricing Analysis

14.4.2. Market Share Analysis, 2022

14.4.2.1. By Drug Class

14.4.2.2. By Route of Administration

14.4.2.3. By Distribution Channel

14.5. Germany

14.5.1. Pricing Analysis

14.5.2. Market Share Analysis, 2022

14.5.2.1. By Drug Class

14.5.2.2. By Route of Administration

14.5.2.3. By Distribution Channel

14.6. United Kingdom

14.6.1. Pricing Analysis

14.6.2. Market Share Analysis, 2022

14.6.2.1. By Drug Class

14.6.2.2. By Route of Administration

14.6.2.3. By Distribution Channel

14.7. France

14.7.1. Pricing Analysis

14.7.2. Market Share Analysis, 2022

14.7.2.1. By Drug Class

14.7.2.2. By Route of Administration

14.7.2.3. By Distribution Channel

14.8. Spain

14.8.1. Pricing Analysis

14.8.2. Market Share Analysis, 2022

14.8.2.1. By Drug Class

14.8.2.2. By Route of Administration

14.8.2.3. By Distribution Channel

14.9. Italy

14.9.1. Pricing Analysis

14.9.2. Market Share Analysis, 2022

14.9.2.1. By Drug Class

14.9.2.2. By Route of Administration

14.9.2.3. By Distribution Channel

14.10. China

14.10.1. Pricing Analysis

14.10.2. Market Share Analysis, 2022

14.10.2.1. By Drug Class

14.10.2.2. By Route of Administration

14.10.2.3. By Distribution Channel

14.11. Japan

14.11.1. Pricing Analysis

14.11.2. Market Share Analysis, 2022

14.11.2.1. By Drug Class

14.11.2.2. By Route of Administration

14.11.2.3. By Distribution Channel

14.12. South Korea

14.12.1. Pricing Analysis

14.12.2. Market Share Analysis, 2022

14.12.2.1. By Drug Class

14.12.2.2. By Route of Administration

14.12.2.3. By Distribution Channel

14.13. Singapore

14.13.1. Pricing Analysis

14.13.2. Market Share Analysis, 2022

14.13.2.1. By Drug Class

14.13.2.2. By Route of Administration

14.13.2.3. By Distribution Channel

14.14. Thailand

14.14.1. Pricing Analysis

14.14.2. Market Share Analysis, 2022

14.14.2.1. By Drug Class

14.14.2.2. By Route of Administration

14.14.2.3. By Distribution Channel

14.15. Indonesia

14.15.1. Pricing Analysis

14.15.2. Market Share Analysis, 2022

14.15.2.1. By Drug Class

14.15.2.2. By Route of Administration

14.15.2.3. By Distribution Channel

14.16. Australia

14.16.1. Pricing Analysis

14.16.2. Market Share Analysis, 2022

14.16.2.1. By Drug Class

14.16.2.2. By Route of Administration

14.16.2.3. By Distribution Channel

14.17. New Zealand

14.17.1. Pricing Analysis

14.17.2. Market Share Analysis, 2022

14.17.2.1. By Drug Class

14.17.2.2. By Route of Administration

14.17.2.3. By Distribution Channel

14.18. GCC Countries

14.18.1. Pricing Analysis

14.18.2. Market Share Analysis, 2022

14.18.2.1. By Drug Class

14.18.2.2. By Route of Administration

14.18.2.3. By Distribution Channel

14.19. South Africa

14.19.1. Pricing Analysis

14.19.2. Market Share Analysis, 2022

14.19.2.1. By Drug Class

14.19.2.2. By Route of Administration

14.19.2.3. By Distribution Channel

14.20. Israel

14.20.1. Pricing Analysis

14.20.2. Market Share Analysis, 2022

14.20.2.1. By Drug Class

14.20.2.2. By Route of Administration

14.20.2.3. By Distribution Channel

15. Market Structure Analysis

15.1. Competition Dashboard

15.2. Competition Benchmarking

15.3. Market Share Analysis of Top Players

15.3.1. By Regional

15.3.2. By Drug Class

15.3.3. By Route of Administration

15.3.4. By Distribution Channel

16. Competition Analysis

16.1. Competition Deep Dive

16.1.1. WEX Pharmaceuticals Inc

16.1.1.1. Overview

16.1.1.2. Product Portfolio

16.1.1.3. Profitability by Market Segments

16.1.1.4. Sales Footprint

16.1.1.5. Strategy Overview

16.1.1.5.1. Marketing Strategy

16.1.2. Jazz Pharmaceuticals

16.1.2.1. Overview

16.1.2.2. Product Portfolio

16.1.2.3. Profitability by Market Segments

16.1.2.4. Sales Footprint

16.1.2.5. Strategy Overview

16.1.2.5.1. Marketing Strategy

16.1.3. Nobelpharma Co., Ltd.

16.1.3.1. Overview

16.1.3.2. Product Portfolio

16.1.3.3. Profitability by Market Segments

16.1.3.4. Sales Footprint

16.1.3.5. Strategy Overview

16.1.3.5.1. Marketing Strategy

16.1.4. Tetra Bio-Pharma Inc.

16.1.4.1. Overview

16.1.4.2. Product Portfolio

16.1.4.3. Profitability by Market Segments

16.1.4.4. Sales Footprint

16.1.4.5. Strategy Overview

16.1.4.5.1. Marketing Strategy

16.1.5. Pfizer

16.1.5.1. Overview

16.1.5.2. Product Portfolio

16.1.5.3. Profitability by Market Segments

16.1.5.4. Sales Footprint

16.1.5.5. Strategy Overview

16.1.5.5.1. Marketing Strategy

16.1.6. Recipharm

16.1.6.1. Overview

16.1.6.2. Product Portfolio

16.1.6.3. Profitability by Market Segments

16.1.6.4. Sales Footprint

16.1.6.5. Strategy Overview

16.1.6.5.1. Marketing Strategy

16.1.7. eurofins

16.1.7.1. Overview

16.1.7.2. Product Portfolio

16.1.7.3. Profitability by Market Segments

16.1.7.4. Sales Footprint

16.1.7.5. Strategy Overview

16.1.7.5.1. Marketing Strategy

16.1.8. Sigma-Aldrich

16.1.8.1. Overview

16.1.8.2. Product Portfolio

16.1.8.3. Profitability by Market Segments

16.1.8.4. Sales Footprint

16.1.8.5. Strategy Overview

16.1.8.5.1. Marketing Strategy

16.1.9. AstraZeneca

16.1.9.1. Overview

16.1.9.2. Product Portfolio

16.1.9.3. Profitability by Market Segments

16.1.9.4. Sales Footprint

16.1.9.5. Strategy Overview

16.1.9.5.1. Marketing Strategy

16.1.10. GlaxoSmithKline plc

16.1.10.1. Overview

16.1.10.2. Product Portfolio

16.1.10.3. Profitability by Market Segments

16.1.10.4. Sales Footprint

16.1.10.5. Strategy Overview

16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Asia Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 19: Asia Pacific Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 20: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 21: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 23: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 24: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033

Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033

Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Asia Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 82: Asia Pacific Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 83: Asia Pacific Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 94: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 97: Asia Pacific Market Attractiveness by Drug Class, 2023 to 2033

Figure 98: Asia Pacific Market Attractiveness by Route of Administration, 2023 to 2033

Figure 99: Asia Pacific Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 101: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 102: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 103: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 104: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 109: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 110: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 111: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 112: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 113: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 114: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 115: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 116: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 117: MIDDLE EAST AND AFRICA Market Attractiveness by Drug Class, 2023 to 2033

Figure 118: MIDDLE EAST AND AFRICA Market Attractiveness by Route of Administration, 2023 to 2033

Figure 119: MIDDLE EAST AND AFRICA Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 120: MIDDLE EAST AND AFRICA Market Attractiveness by Country, 2023 to 2033